Cytokinetics pharmaceuticals stock

Author: hqbd

August undefined, 2024

WebJan 8, 2024 · According to the 10-Q SEC Filing, Cytokinetics had cash, cash equivalents and investments of $668.9 million as of September 30, 2024. A big reason for the cash on hand was because of an offering... WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.

Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You …

WebMar 31, 2024 · Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) SOUTH SAN FRANCISCO, Calif. , April 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) … WebApr 10, 2024 · Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.73 based on yesterday's closing prices. The Large Cap Pharmaceuticals industry is part of the Medical sector. greaves hockey stick

Cytokinetics (CYTK) Dips 20% so Far in 2024 on Setbacks - Yahoo …

WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Our Vision Leadership … WebApr 5, 2024 · CYTOKINETICS, INCORPORATED : News, information and stories for CYTOKINETICS, INCORPORATED Nasdaq: CYTK Nasdaq ... VERTEX PHARMACEUTICALS INCORPORATED : Q1 2024 Earnings Release (Projected) 05/04/23: ... Stock quotes are provided by Factset, Morningstar and S&P Capital IQ WebApr 11, 2024 · EDMONTON, Alberta, April 11, 2024 -- ( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office... florist in woodway tx

Analysts Have Conflicting Sentiments on These Healthcare …

WebDec 20, 2024 · The CSPAs provide for the sale and issuance to the RTW Investors of 511,182 shares of Cytokinetics common stock of (the "Shares") with an aggregate purchase price of $20.0 million at a price per share of $39.125. The closing will occur on December 20, 2024. WebApr 9, 2024 · Cytokinetics Trading Up 0.7 %. Cytokinetics stock opened at $36.42 on Friday. The business’s 50 day simple moving average is $39.79 and its 200 day simple moving average is $42.22. greaves house rochdaleWebApr 10, 2024 · The company’s shares closed last Thursday at $78.78. Kumar covers the Healthcare sector, focusing on stocks such as Cytokinetics, Syndax Pharmaceuticals, and Fulcrum Therapeutics. According to... florist in yorktown heights ny

"WebApr 29, 2004 · Cytokinetics is registered under the ticker NASDAQ:CYTK . Their stock opened with $13.00 in its Apr 29, 2004 IPO. Cytokinetics is funded by 5 investors. Royalty Pharma and Deerfield are the most recent investors. Cytokinetics has invested in The Mended Hearts on Jan 30, 2024. This investment - Grant - The Mended Hearts - was … " - Cytokinetics pharmaceuticals stock

Cytokinetics pharmaceuticals stock

Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote

WebApr 10, 2024 · It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated CYTK. Shares of the company have moved down 20.5% compared with the industry’s decline of... WebDec 13, 2024 · SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal...

Did you know?

WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. Investor Overview Stock … WebApr 10, 2024 · Zacks Equity Research. April 10, 2024, 9:23 AM · 3 min read. It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated …

Web12 hours ago · In a report released yesterday, Madhu Kumar from Goldman Sachs maintained a Buy rating on Cytokinetics. The company’s shares closed last Thursday at $35.93, close to its 52-week low of $32.96. WebMar 6, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance.

WebCytokinetics, Incorporated (CYTK) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 36.42 +0.26 (+0.72%) At close: 04:00PM EDT. 35.69 -0.73 ( … WebCytokinetics Inc (CYTK) Stock Price Today, News, Quotes, FAQs and Fundamentals 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. CYTK Cytokinetics Inc 3,105 $33.36 $0.27 (0.80%) Today Sentiment 0.00% Message Vol. 42.11% Volume (M) 720,685.00 52-Wk High $55.80 52-Wk Low $33.37 About Feed …

WebMar 7, 2024 · Cytokinetics (Nasdaq:CYTK) earnings and revenue forecasts, price targets, future return on equity. ... President & Director exercised options and sold US$333k worth of stock Aug 04. Cytokinetics GAAP EPS of -$0.23 beats by $0.81, revenue of $88.97M beats by $85.24M ... High growth companies in the Pharmaceuticals & Biotech industry.

WebNov 3, 2024 · Cytokinetics (CYTK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $0.95 per share a year ago. florist james street westportWebJul 19, 2024 · Shares of the little biotech firm Cytokinetics jumped by as much as 60% Monday morning, on the results from a study of the firm’s investigational drug for a … greaves hull cityWebMar 31, 2024 · Cytokinetics' heart disease drug, aficamten, is a "crown jewel in terms of the pipeline", said Oppenheimer analyst Justin Kim, who expects it could bring more than $1 billion in peak sales from U ... greaves houseWebJan 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. florist ipohWebNov 30, 2024 · PDUFA Target Action Date Set for November 30, 2024. FDA is Currently Not Planning to Hold an Advisory Committee Meeting to Discuss the Application SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has … greaves insulated connectorsWebApr 6, 2024 · CYTK Complete Cytokinetics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Cytokinetics Inc. Cytokinetics, Inc. is a biopharmaceutical company, which is … Ligand Pharmaceuticals stock price target raised to $155 from $135 at Benchmark … ACOR Complete Acorda Therapeutics Inc. stock news by MarketWatch. View real … Cytokinetics Inc. analyst estimates, including CYTK earnings per share … Cytokinetics Inc. Annual stock financials by MarketWatch. View the latest CYTK … Cytokinetics Inc. advanced stock charts by MarketWatch. View CYTK historial stock … greaves in cat foodWebApr 5, 2024 · About Cytokinetics (NASDAQ:CYTK) Stock. Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and … florist in yelm wa